株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のワクチン受託製造市場の予測:2018年〜2028年

Global Vaccine Contract Manufacturing Market Report 2018-2028: Leading Countries, Technologies and Companies

発行 Visiongain Ltd 商品コード 347364
出版日 ページ情報 英文 150 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=150.55円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
世界のワクチン受託製造市場の予測:2018年〜2028年 Global Vaccine Contract Manufacturing Market Report 2018-2028: Leading Countries, Technologies and Companies
出版日: 2018年03月06日 ページ情報: 英文 150 Pages
概要

世界のワクチン受託製造市場は、2017年〜2022年のCAGR (複合年間成長率) で、9.1%の成長が予測されています。

当レポートでは、世界のワクチン受託製造市場について調査分析し、収益と成長予測、市場シェア、主要国、主要企業、動向とSWOT分析など、体系的な情報を提供しています。

第1章 レポート概要

第2章 ワクチンについて

  • ワクチンの歴史
  • ワクチンの仕組み
    • 人工免疫
  • ワクチンの種類
    • 弱毒生ワクチン (LAV)
    • 組換え生ワクチン
    • 不活化ワクチン
    • トキソイドワクチン
    • サブユニットワクチン
    • 共役ワクチン
    • 組換えサブユニットワクチン
    • DNAワクチン
    • 組換えベクターワクチン
    • 治療ワクチン
  • ワクチンで予防できる疾患
  • ワクチン市場の成長
  • 技術・法規制の改善

第3章 ワクチン製造技術

  • ワクチン技術動向のサマリー
  • ワクチン製造の新基質
  • 次世代発現システムとベクター
  • 器具の動向
  • プレフィルドシリンジ (薬液充填済み注射器) とワクチン
  • 凍結乾燥とワクチン製造
  • 細胞培地

第4章 世界のワクチン製造市場

  • 世界のワクチン製造市場の概要
  • 世界のワクチン市場の予測
  • 世界のワクチン市場:二次市場別
  • ワクチン市場の成長がワクチン製造の効率を促進
  • 小児用ワクチン市場の概要
  • 成人用予防ワクチン市場の概要
  • インフルエンザワクチン市場の概要
  • 治療ワクチン市場の概要

第5章 世界のワクチン受託製造

  • 医薬品・バイオテクノロジー産業におけるアウトソーシング
  • 医薬品受託製造機関 (CMO)
  • 医薬品受託製造市場:総収益の予測
  • ワクチン受託製造市場

第6章 主要国のワクチン受託製造市場

  • 主要国のワクチン受託製造市場
  • 主要国のワクチン受託製造市場 (実績)
  • 主要国のワクチン受託製造市場 (予測)

第7章 ワクチン受託製造の主要企業

  • 主なワクチン受託製造機関
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent
  • Charles River Laboratories
  • IDT Biologika GmbH
  • Lonza
  • Meridian Life Science
  • Sigma-Aldrich Fine Chemicals (SAFC) (Merck KGaA)
  • SynCo Bio Partners

第8章 ワクチン製造市場:世界市場の動向

  • ワクチン受託製造業の動向
  • SWOT分析

第9章 結論

付録

目次
Product Code: PHA0292

The global vaccine contract manufacturing market was worth $883.0m in 2017 and is expected to grow at a CAGR of 9.1% from 2017-2022. Visiongain predicts a CAGR of 9.2% for the global vaccine contract manufacturing market over the whole forecast period (2017-2028).

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 150-page report you will receive 69 charts- all unavailable elsewhere.

The 150-page report provides clear detailed insight into the global vaccine contract manufacturing market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Revenue and growth forecasts to 2028 for the global vaccine market and market shares in 2017 and 2018 of the submarkets: paediatric vaccines, adult vaccines, influenza vaccines and therapeutic vaccines
  • Revenue and growth forecasts to 2028 for the global vaccine contract manufacturing market
  • Revenue and growth forecasts to 2028 for the leading national markets:
  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
  • Brazil
  • Russia
  • China
  • India
  • Rest of the World

image1

  • Discussion and profiles of the leading players in the vaccine contract manufacturing market:
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent
  • Charles River Laboratories
  • IDT Biologika
  • Lonza
  • Meridian Life Science
  • Sigma Aldrich Fine Chemicals
  • Merck
  • Synco Bio Partners
  • Analysis of what stimulates and restrains the global vaccine contract manufacturing market: Trends and SWOT Analysis

Visiongain's study is intended for anyone requiring commercial analyses for the global vaccine contract manufacturing market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 World Vaccine Contract Manufacturing Market Highlights
  • 1.2 Why You Should Read This Report?
  • 1.3 How This Report Delivers
  • 1.4 Key Questions Answered by This Analytical Report
  • 1.5 Who is This Report For?
  • 1.6 Methodology
  • 1.7 Associated Visiongain Reports
  • 1.8 Frequently Asked Questions (FAQ)

2. Introduction to Vaccines

  • 2.1 The History of Vaccines
  • 2.2 How Do Vaccines Work?
    • 2.2.1 Artificial Immunity
  • 2.3 Types of Vaccine
    • 2.3.1 Live, Attenuated Vaccines (LAVs)
    • 2.3.2 Recombinant Live Vaccines
    • 2.3.3 Inactivated Vaccines
    • 2.3.4 Toxoid Vaccines
    • 2.3.5 Subunit Vaccines
    • 2.3.6 Conjugate Vaccines
    • 2.3.7 Recombinant Subunit Vaccines
    • 2.3.8 DNA Vaccines
    • 2.3.9 Recombinant Vector Vaccines
    • 2.3.10 Therapeutic Vaccines
  • 2.4 Diseases Preventable with Vaccines
  • 2.5 The Rise of the Vaccines Market
  • 2.6 Technological and Regulatory Improvements

3. Vaccine Manufacturing Technologies, 2017

  • 3.1 Summary of Vaccine Technology Trends
  • 3.2 New Substrates for Vaccine Production
    • 3.2.1 Shift towards Cell-Based Manufacturing Technology
    • 3.2.2 Benefits of Cell-Based Techniques
    • 3.2.3 Mammalian Cell Lines
      • 3.2.3.1 MCDK (Madin Darby Canine Kidney Cells)
      • 3.2.3.2 Vero Cells
      • 3.2.3.3 PerC6 Cells
    • 3.2.4 Avian-Derived Cell Lines
      • 3.2.4.1 EB66 Stem Cell Technology: Vivalis
    • 3.2.5 Plant-Based Vaccines
      • 3.2.5.1 Medicago's Proficia VLP Vaccine Technology
    • 3.2.6 Insect Egg-Based Production Systems
      • 3.2.6.1 Novavax
      • 3.2.6.2 Protein Sciences Corporation (PSC)
  • 3.3 Next-Generation Expression Systems and Vectors: Increasing Production Yield
    • 3.3.1 AdVac Technology: Crucell
    • 3.3.2 AdCEV Vectors: AfriVax
    • 3.3.3 Pfenex Expression Technology: Pfenex
  • 3.4 Equipment Trends
    • 3.4.1 The Shift Towards Disposable Single-use Equipment
    • 3.4.2 Bioreactors and Vaccine Production
      • 3.4.2.1 Single-Use Bioreactors
      • 3.4.2.2 Main Applications of Disposable Bioreactors
      • 3.4.2.3 Current Single-Use Bioreactor Systems on the Market
  • 3.5 Prefilled Syringes and Vaccines
    • 3.5.1 Growing Market for Pre-Filled Syringes
    • 3.5.2 Pre-Filled Vaccine Products
    • 3.5.3 Drivers and Restraints for Pre-Filled Syringes
    • 3.5.4 Product Stability and Quality Assurance Programme
      • 3.5.4.1 Paediatric H1N1 Vaccine
      • 3.5.4.2 Reported Challenges Flu Vaccines
      • 3.5.4.3 Novartis' Agriflu and Fluad Ban is Lifted
      • 3.5.4.4 Baxter Flu Vaccine and Side Effects
      • 3.5.4.5 Reported Shelf Life with H1N1 Vaccine
  • 3.6 Lyophilisation and Vaccine Manufacturing
    • 3.6.1 Lyophilisation of Vaccines Will Increase
  • 3.7 Cell Media Can Improve Virus Yield

4. The Global Vaccine Manufacturing Market 2018-2028

  • 4.1 Overview of the Global Vaccine Manufacturing Market 2018-2028
  • 4.2 World Vaccine Market Forecast 2018-2028
  • 4.3 The Global Vaccine Market by Submarket, 2016 and 2017
  • 4.4 Growth in Vaccine Market Will Drive Efficiency in Vaccine Manufacturing
  • 4.5 Paediatric Vaccines Market Overview
  • 4.6 Adult Prophylactic Vaccines Market Overview
  • 4.7 Influenza Vaccines Market Overview
  • 4.8 Therapeutic Vaccines Market Overview

5. The Global Vaccine Contract Manufacturing 2018-2028

  • 5.1 Outsourcing in the Pharmaceutical and Biotechnology Industry
    • 5.1.1 Reasons to Outsource
    • 5.1.2 Benefits of Outsourcing
    • 5.1.3 The Challenges in Outsourcing Vaccine Manufacturing
    • 5.1.4 Why Should Companies Outsource Vaccine Manufacturing?
    • 5.1.5 Strategic Outsourcing vs. Tactical Outsourcing
    • 5.1.6 Virtual Companies
  • 5.2 Contract Manufacturing Organisations (CMOs)
    • 5.2.1 Manufacturing Services Offered by CMOs
    • 5.2.2 Vaccine Manufacturing Activities Typically Outsourced
  • 5.3 The Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast 2016-2028
  • 5.4 Contract Manufacturing Market for Vaccines 2017-2028
    • 5.4.1 Market Size for Contract Manufacturing of Vaccines 2017
    • 5.4.2 Vaccine Contract Manufacturing Market Forecast 2017-2028

6. The Leading National Markets for Vaccine Contract Manufacturing, 2018-2028

  • 6.1 The Leading National Markets for Vaccine Contract Manufacturing
  • 6.2 The Leading National Markets for Vaccine Contract Manufacturing, 2016-2017
  • 6.3 The Leading National Markets for Vaccine Contract Manufacturing, 2017-2028
    • 6.3.1 The US Vaccine Contract Manufacturing Market Forecast, 2017-2028
    • 6.3.2 The EU5 Vaccine Contract Manufacturing Market, 2016 and 2017
      • 6.3.2.1 The EU5 Vaccine Contract Manufacturing Market, 2016-2028
      • 6.3.2.2 The German Vaccine Contract Manufacturing Market, 2016-2028
      • 6.3.2.3 The Italian Vaccine Contract Manufacturing Market, 2018-2028
      • 6.3.2.4 The UK Vaccine Contract Manufacturing Market, 2018-2028
      • 6.3.2.5 The French Vaccine Contract Manufacturing Market, 2018-2028
      • 6.3.2.6 The Spanish Vaccine Contract Manufacturing Market, 2018-2028
    • 6.3.3 The Japanese Vaccine Contract Manufacturing Market, 2018-2028
    • 6.3.4 The Chinese Vaccine Contract Manufacturing Market, 2018-2028
    • 6.3.5 The Indian Vaccine Contract Manufacturing Market, 2018-2028
    • 6.3.6 The Russian Vaccine Contract Manufacturing Market, 2018-2028
    • 6.3.7 The Brazilian Vaccine Contract Manufacturing Market, 2018-2028

7. Leading Vaccine Contract Manufacturing Companies, 2018-2028

  • 7.1 Leading Vaccine Contract Manufacturing Organisations
  • 7.2 Baxter BioPharma Solutions
  • 7.3 Boehringer Ingelheim
    • 7.3.1 Recent Financial Performance
    • 7.3.2 Ben Venue Laboratories
    • 7.3.3 Manufacturing Deals 2011-2017
  • 7.4 Catalent
    • 7.4.1 Recent Financial Performance
    • 7.4.2 Catalent: Financial Performance by Segment, 2011-2016
    • 7.4.3 Catalent Injectable Vaccines
    • 7.4.4 Catalent: Zydis Technology
    • 7.4.5 Regional Market Expansion Strategy
  • 7.5 Charles River Laboratories
    • 7.5.1 Recent Financial Performance, 2010-2016
    • 7.5.2 Financial Performance by Segment, 2010-2016
    • 7.5.3 Vaccine Manufacturing Services
    • 7.5.4 Charles River Avian Vaccine Services
    • 7.5.5 Vaccine Manufacturing Expansion
    • 7.5.6 Outlook and Early Stage Restructuring
    • 7.5.7 Partnerships
      • 7.5.7.1 Partnership with AstraZeneca
      • 7.5.7.2 Partnership with Batavia
  • 7.6 IDT Biologika GmbH
  • 7.7 Lonza
    • 7.7.1 Recent Financial Performance
    • 7.7.2 Manufacturing Division Restructuring
  • 7.8 Meridian Life Science
    • 7.8.1 Recent Financial Performance, 2010-2016
    • 7.8.2 Recent Financial Performance by Segment, 2011-2016
  • 7.9 Sigma-Aldrich Fine Chemicals (SAFC) (Merck KGaA)
  • 7.10 SynCo Bio Partners
    • 7.10.1 Recent Developments
      • 7.10.1.1 Expansion of Facilities
      • 7.10.1.2 FDA Approval of Partner Application

8. Vaccine Manufacturing Market: World Market Trends 2018-2028

  • 8.1 Vaccine Contract Manufacturing Industry Trends
  • 8.2 Strengths
    • 8.2.1 Many Companies Cannot Afford In-house Capabilities
    • 8.2.2 Outsourcing Improves Time to Market
    • 8.2.3 Manufacturers Get Access to Specialised Technologies
    • 8.2.4 Shift Towards Emerging Markets as Favourable Outsourcing Destinations
  • 8.3 Weaknesses
    • 8.3.1 Mass Vaccine Manufacturing Kept In-house
    • 8.3.2 A Highly-Fragmented Vaccine Contract Manufacturing Market
    • 8.3.3 An Unpredictable Supply and Demand Business Model
  • 8.4 Opportunities
    • 8.4.1 Many Vaccines in the Product Pipeline
    • 8.4.2 Emerging Market's Growing Demand for Vaccines
    • 8.4.2.1 Dynamic Change: Emerging Markets are Major Vaccine Developers
    • 8.4.3 Changing World Demographics
  • 8.5 Threats
    • 8.5.1 Post Recession: Biotech Suffer from Severe Cuts in Capital Funding
    • 8.5.2 The Public are Slow to Accept Novel Technologies
    • 8.5.3 Perception of Risk by the Original Vaccine Manufacturers

9. Conclusion

  • 9.1 Overview
  • 9.2 Regulatory and Quality Standards Create High Barriers of Entry
  • 9.3 Emerging Markets Will Show Stronger Growth

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Tables

  • Table 2.1 Timeline of Key Events in Vaccine Development, c.1000 AD - Present
  • Table 3.1 Vaccine Development Pipeline Using Crucell's AdVac Technology
  • Table 3.2 Benefits and Drawbacks of Using Disposable Technology for Vaccine Production
  • Table 3.3 Companies Providing Disposable Biomanufacturing Platforms/Systems
  • Table 3.4 Some Leading Pre-Filled Syringe Vaccine Products
  • Table 3.5 Prominent Lyophilised Vaccines
  • Table 3.6 Examples of Serum-Free Media for Vaccine Manufacturing
  • Table 4.1 The Global Vaccine Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2017-2028
  • Table 4.2 The Global Vaccine Market: Revenue ($bn) and Market Share by Submarket (%), 2017-2018
  • Table 5.1 The Global Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.1 The Leading National Vaccine Contract Manufacturing Markets Forecast: Revenue ($m) and Market Share (%), 2017-2018
  • Table 6.2 The US Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.3 The EU5 National Vaccine Contract Manufacturing Markets: Revenue ($m) and Market Share (%) by Country, 2017-2018
  • Table 6.4 The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.5 The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.6 The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.7 The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.8 The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.9 The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.10 The Japanese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.11 The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.12 The Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.13 The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.14 The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 7.1 Boehringer Ingelheim: Biopharmaceuticals Revenue ($m) and Annual Growth Rate (%), 2010-2016
  • Table 7.2 Catalent: Revenue($m) and AGR (%), 2010-2016
  • Table 7.3 Catalent by Segment: Revenue($m), AGR (%), and Intersegment Revenue Eliminations, 2011-2016
  • Table 7.4 Charles River Laboratories: Revenue ($bn) and AGR (%), 2010-2015
  • Table 7.5 Charles River Laboratories: Newly Revised Reportable Segments
  • Table 7.6 Charles River Laboratories: cGMP Vaccine Manufacturing and Testing Capabilities
  • Table 7.7 Lonza Custom Manufacturing: Revenue ($m) and AGR (%), 2010-2016
  • Table 7.8 Meridian Bioscience: Revenue ($m), AGR (%), 2010-2016
  • Table 7.9 Meridian Bioscience: Revenue ($m) and AGR (%) by Segment, 2011-2016
  • Table 7.10 SynCo Bio Partners Capabilities
  • Table 8.1 SWOT Analysis of the Vaccine Contract Manufacturing Market

List of Figures

  • Figure 3.1 Influenza Vaccine Production Using a Cell-Based Manufacturing Method
  • Figure 3.2 Medicago's Product Pipeline
  • Figure 3.3 Novavax' Insect Egg-Based Vaccine Production Process
  • Figure 3.4 Pre-filled Syringes Market: Drivers and Restraints, 2018-2028
  • Figure 4.1 The Global Vaccine Market Forecast: Revenue ($bn), AGR (%) 2017-2028
  • Figure 4.2 The Global Vaccine Market: Market Share by Submarket (%), 2017
  • Figure 5.1 Selected Tasks Outsourced in the Pharmaceutical and Biotech Industry
  • Figure 5.2 The Global Vaccine Contract Manufacturing Forecast: Revenue ($m), 2017, 2022 and 2028
  • Figure 5.3 The Global Vaccine Contract Manufacturing Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.1 The Leading National Vaccine Contract Manufacturing Markets: Market Share (%) by Region, 2017
  • Figure 6.2 The US Vaccine Contract Manufacturing Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.3 The EU5 Vaccine Contract Manufacturing Markets: Market Share (%) by Country, 2017
  • Figure 6.4 The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.5 The EU5 Vaccine Contract Manufacturing Markets: Market Share (%) by Country, 2018
  • Figure 6.6 The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.7 The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.8 The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.9 The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.10 The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.11 The Japanese Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Figure 6.12 The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%) 2017-2028
  • Figure 6.13 The Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%) 2017-2028
  • Figure 6.14 The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.15 The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2017-2028
  • Figure 7.1 Boehringer Ingelheim: Biopharmaceuticals Revenue ($m) and Annual Growth Rate (%), 2010-2016
  • Figure 7.2 Catalent: Revenue ($m) and AGR (%), 2010-2016
  • Figure 7.3 Catalent: Revenue ($m) by Segment, 2011-2016
  • Figure 7.4 Catalent: Market Shares (%) by Segment, 2016
  • Figure 7.5 Charles River Laboratories: Revenue ($bn) and AGR (%), 2010-2016
  • Figure 7.6 Lonza Custom Manufacturing: Revenue ($m) and AGR (%), 2010-2016
  • Figure 7.7 Meridian Bioscience: Revenue ($m), and AGR (%), 2010-2016
  • Figure 7.8 Meridian Bioscience: Revenue ($m) by Segment, 2011-2016
  • Figure 7.9 Meridian Bioscience: Market Share (%) by Segment,2016
  • Figure 8.1 Drivers and Restraints for the Vaccine Contract Manufacturing Sector

Companies Listed

  • Accugenix
  • Aeras Global
  • AfriVax
  • Amgen
  • AmProtein
  • Antigenics Inc.
  • Artelis
  • AstraZeneca
  • ATM Life Sciences
  • ATMI
  • AVEO Pharmaceuticals
  • Bacteriological Institute of the Anhaltian Administrative Areas
  • Batavia Bioservices
  • Baxter
  • Baxter BioPharma Solutions
  • Bayer
  • Beijing Tiantan Biological Productions
  • Ben Venue Laboratories
  • Berna Biotech
  • Bharat Biotech International Limited
  • Binnopharm
  • BioKangtai
  • Biovest
  • Boehringer Ingelheim
  • Boehringer Ingelheim Biopharmaceuticals (China)
  • Boehringer Ingelheim BioXcellence
  • Cadila Pharmaceuticals
  • Catalent
  • Cellexus Limited
  • Charles River Laboratories
  • Chengdu Institute of Biological Products Co.
  • China National Biotec Group Co., Ltd. (CNBG)
  • Crucell
  • CSL Biotherapies
  • Daiichi Sankyo Co. Ltd.
  • Dalian Hissen Bio-Pharm
  • Dendreon
  • Elanco Animal Health
  • Eli Lilly
  • Farmindustria
  • FiberCell
  • Gallant Custom Laboratories
  • GE Healthcare
  • GE Healthcare Life Sciences
  • GE Wave Biotech
  • Gelita
  • GlaxoSmithKline (GSK)
  • GlaxoSmithKline Biologics
  • Hikma
  • Hualan Biological Bacterin
  • Hyclone
  • IDT Biologika GmbH
  • Impfstoffwerk Dessau-Tornau GmbH (IDT)
  • Institut Pasteur
  • Intercell Corporation
  • Invitrogen
  • Irvine Scientific
  • Klocke Group
  • Kuhner
  • LG Life Sciences
  • Lonza
  • Medicago
  • Medimmune
  • Meissner Filtration
  • Merck & Co.
  • Merck KGaA
  • Merck Millipore
  • Merck Serono
  • Meridian Bioscience
  • Meridian Life Science
  • MGC Pharma Co.
  • Micron Technologies
  • Millipore
  • Mitsubishi Tanabe Pharma (MTPC)
  • MorphoSys
  • MP Biomedicals
  • Novartis
  • Novartis Vaccines and Diagnostics
  • Novavax
  • Organon Teknika Corporation
  • Pall Life Sciences
  • Paragon Bioservices
  • Patheon
  • PaxVax Corporation
  • PBS Biotech
  • Pfenex
  • Pfizer
  • Pharmaceutical Base Development Co., Ltd.
  • Philip Morris
  • Philip Morris Investments
  • Pierre-Guerin Biolafitte
  • Protein Sciences Corporation
  • Refine Technology
  • Sanofi
  • Sanofi Pasteur
  • Sanofi Pasteur MSD
  • Sartorius Stedim
  • Shanghai Zhangjiang Biotech
  • ShangPharma Corporation
  • Sigma Aldrich
  • Sigma-Aldrich Fine Chemicals (SAFC)
  • Sunrise Farms, Inc.
  • SynCo Bio Partners (SynCo)
  • Thermo Fisher
  • Vector Solutions
  • Vivalis
  • Wave Biotech
  • Wyeth
  • Xcellerex
  • Xencor
  • ZellWerk
  • Zhejiang Jiang Yuan Tang Biotechnology Corporation

List of Organisations Mentioned in the Report

  • Biomedical Advanced Research and Development Authority (BARDA)
  • Center for Disease Control (CDC)
  • China Food and Drug Administration (CFDA)
  • Defense Advanced Research Projects Agency (DARPA)
  • Department of Health and Human Services (HHS)
  • Emory University
  • European Medical Agency
  • Food and Drug Administration (FDA)
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • PATH
  • U.S. Department of Health and Human Services Office
  • U.S. Department of Homeland Security
  • World Health Organisation (WHO)
Back to Top